|
421 |
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
Enthalten in Nature medicine 20.6.2024: 1-10
|
|
|
|
422 |
Probiotic-Reduced Inflammaging in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
Enthalten in Probiotics and Antimicrobial Proteins 19.6.2024: 1-11
|
|
|
|
423 |
Rho-kinase inhibition reduces systolic blood pressure and forearm vascular resistance in healthy older adults: a double-blind, randomized, placebo-controlled pilot study
Enthalten in GeroScience 18.6.2024: 1-13
|
|
|
|
424 |
Wundermittel Naltrexon? – Bei Fibromyalgie nicht wirksamer als Placebo
Enthalten in Zeitschrift für Allgemeinmedizin 18.6.2024: 1-2
|
|
|
|
425 |
Effects of Bifidobacterium breve 207-1 on regulating lifestyle behaviors and mental wellness in healthy adults based on the microbiome-gut-brain axis: a randomized, double-blind, placebo-controlled trial
Enthalten in European journal of nutrition 13.6.2024: 1-19
|
|
|
|
426 |
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
Enthalten in Endocrine 8.6.2024: 1-15
|
|
|
|
427 |
Sex differences in the acute effects of oral THC: a randomized, placebo-controlled, crossover human laboratory study
Enthalten in Psychopharmacology 4.6.2024: 1-11
|
|
|
|
428 |
Wirksamkeit von Teprotumumab bei der chronischen endokrinen Orbitopathie
Enthalten in Kompass Autoimmun Bd. 6, 2024, Nr. 2: 81-82. 2 S.
|
|
|
|
429 |
Systemischer Lupus erythematodes: Neue Hoffnung durch Baricitinib-Therapie?
Enthalten in Kompass Autoimmun Bd. 6, 2024, Nr. 2: 74-76. 3 S.
|
|
|
|
430 |
Morbus Crohn: Vielversprechende Behandlungsoption eines neuen IL-23-Inhibitors auf dem Weg zur Zulassung
Enthalten in Kompass Autoimmun Bd. 6, 2024, Nr. 2: 66-69. 4 S.
|
|
Administration
